Budget impact model of avelumab in patients with metastatic merkel cell carcinoma in the US
Murtuza Bharmal,1 Mairead Kearney,1 Ying Zheng,2 Hemant Phatak21Global Evidence and Value Development, Merck Healthcare KGaA, Darmstadt, Germany; 2US Health Economics and Outcomes Research, EMD Serono, Inc, Rockland, MA, USAObjective: To estimate the budget impact of avelumab as a treatment option f...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2019-05-01
|
| Series: | ClinicoEconomics and Outcomes Research |
| Subjects: | |
| Online Access: | https://www.dovepress.com/budget-impact-model-of-avelumab-in-patients-with-metastatic-merkel-cel-peer-reviewed-article-CEOR |